Investors really like the sound of IntriCon this year.
The company, getting traction on a multiyear quest to disrupt a hearing aid market dominated by five huge firms, also operates a larger, fast-growing microcomponent business that supplies Medtronic and other medical-device makers.
Analyst Jonathan Block, in a recent update titled, "Can You Hear Me Now," extolled better than projected first-half results for the global designer and maker of tiny, body-worn microelectronic devices.
IntriCon, the best Minnesota public company to own so far in 2018 with a return of over 200 percent, has run from about $6 per share in 2016 to a high of $69.50 per share earlier this month.
"The company has a tremendous amount of momentum in both its medical and hearing businesses," Block wrote to investors after IntriCon reported second-quarter results. "And we believe the runway for both opportunities reaches beyond 2020."
Some longtime shareholders have taken profits in IntriCon recently.
Regardless, trading volume has increased and new investors have taken up the slack, even as IntriCon increased shares outstanding by 25 percent.
Heartland Advisors of Milwaukee, which owned 8 percent of IntriCon at the beginning of the year, sold out as the stock soared this year.